Genetic Variants Linked to Reduced Effectiveness of Popular GLP-1 Weight Loss Drugs
Updated
Updated · ScienceAlert · Apr 15
Genetic Variants Linked to Reduced Effectiveness of Popular GLP-1 Weight Loss Drugs
52 articles · Updated · ScienceAlert · Apr 15
New research has identified genetic variants that make GLP-1 weight loss and diabetes drugs, such as Ozempic and Wegovy, less effective for around 10% of people.
Variants in the PAM gene and GLP1R gene can cause 'GLP-1 resistance,' leading to higher hormone levels but reduced biological response to these medications.
These findings could pave the way for more personalized obesity and diabetes treatments, as genetic testing may help predict individual responses to GLP-1 drugs.
GLP-1s have benefits beyond weight loss. Should genetics even decide who gets them?
A gene variant can make Ozempic's side effects 15 times worse. Should screening be mandatory?
With new genetic tests, could your insurer deny coverage for weight-loss drugs?
Genetics predict weight loss on Wegovy, but is lifestyle still the bigger factor?
As DNA tests for drug response arrive, are we creating a new form of health inequality?
Pharmacogenomics of GLP-1 Receptor Agonists: Impact of GLP1R and GIPR Variants on Efficacy and Tolerability
Overview
Recent genetic research has identified specific variants that affect how patients respond to GLP-1 receptor agonists used for diabetes and obesity. For example, the GLP1R variant rs10305420 enhances weight loss, especially common in people of European ancestry, while the GIPR variant rs1800437 increases the risk of vomiting with certain drugs like tirzepatide. These side effects often lead to changes in medication. Genetic testing services now offer personalized reports predicting weight loss and side effect risks, but genetics explains only about a quarter of treatment variability. Meanwhile, GLP-1 receptor agonists also provide significant cardiovascular benefits, though no genetic links to these effects have been found yet.